21 Einträge gefunden

1. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

   1. Facon, Thierry
   2. Kumar, Shaji K
   3. Plesner, Torben
   4. Orlowski, Robert Z
   5. Moreau, Philippe
   6. Bahlis, Nizar
   7. Basu, Supratik

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

   1. Facon, Thierry
   2. Cook, Gordon
   3. Usmani, Saad Z
   4. Hulin, Cyrille
   5. Kumar, Shaji
   6. Plesner, Torben
   7. Touzeau, Cyrille

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

   1. Hillengass, Jens
   2. Cohen, Adam D
   3. Delforge, Michel
   4. Einsele, Hermann
   5. Goldschmidt, Hartmut
   6. Weisel, Katja
   7. Raab, Marc-Steffen

   2022 - Forschungsinformationssystem des UKE
4. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
5. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

   1. Mateos, Maria-Victoria
   2. Weisel, Katja
   3. De Stefano, Valerio
   4. Goldschmidt, Hartmut
   5. Delforge, Michel
   6. Mohty, Mohamad
   7. Cavo, Michele

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
6. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

   1. Piechotta, Vanessa
   2. Skoetz, Nicole
   3. Engelhardt, Monika
   4. Einsele, Hermann
   5. Goldschmidt, Hartmut
   6. Scheid, Christof

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
7. MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

   1. Stroh, Jacob
   2. Seckinger, Anja
   3. Heider, Michael
   4. Rudelius, Martina
   5. Eichner, Ruth
   6. Schick, Markus
   7. Slawska, Jolanta

   2022 - Forschungsinformationssystem des UKE
8. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

   1. Dimopoulos, Meletios A
   2. Richardson, Paul G
   3. Bahlis, Nizar J
   4. Grosicki, Sebastian
   5. Cavo, Michele
   6. Beksaç, Meral
   7. Legieć, Wojciech

   2022 - Forschungsinformationssystem des UKE
9. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Bertsch, Uta
   4. Fenk, Roland
   5. Nievergall, Eva
   6. Tichy, Diana
   7. Besemer, Britta

   2022 - Forschungsinformationssystem des UKE
10. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

    1. Goldschmidt, Hartmut
    2. Baertsch, Marc-Andrea
    3. Schlenzka, Jana
    4. Becker, Natalia
    5. Habermehl, Christina
    6. Hielscher, Thomas
    7. Raab, Marc-Steffen

    2021 - Forschungsinformationssystem des UKE
11. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    1. Facon, Thierry
    2. Kumar, Shaji K
    3. Plesner, Torben
    4. Orlowski, Robert Z
    5. Moreau, Philippe
    6. Bahlis, Nizar
    7. Basu, Supratik

    2021 - Forschungsinformationssystem des UKE
12. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

    1. Weisel, Katja
    2. Majer, Istvan
    3. DeCosta, Lucy
    4. Oriol, Albert
    5. Goldschmidt, Hartmut
    6. Ludwig, Heinz
    7. Campioni, Marco

    2020 - Forschungsinformationssystem des UKE
13. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

    1. Dimopoulos, Meletios A
    2. Jakubowiak, Andrzej J
    3. McCarthy, Philip L
    4. Orlowski, Robert Z
    5. Attal, Michel
    6. Bladé, Joan
    7. Goldschmidt, Hartmut

    2020 - Forschungsinformationssystem des UKE
14. Response-adapted lenalidomide maintenance in newly diagnosed myeloma:results from the phase III GMMG-MM5 trial

    1. Goldschmidt, Hartmut
    2. Mai, Elias K
    3. Dürig, Jan
    4. Scheid, Christof
    5. Weisel, Katja C
    6. Kunz, Christina
    7. Bertsch, Uta

    2020 - Forschungsinformationssystem des UKE
15. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

    1. Weisel, Katja
    2. Ludwig, Heinz
    3. Rieth, Achim
    4. Lebioda, Andrea
    5. Goldschmidt, Hartmut

    2020 - Forschungsinformationssystem des UKE
16. Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

    1. Fenk, Roland
    2. Giagounidis, Aristoteles
    3. Goldschmidt, Hartmut
    4. Heinsch, Michael
    5. Rummel, Mathias
    6. Kroger, Nicolaus
    7. Boquoi, Amelie

    2020 - Forschungsinformationssystem des UKE
17. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

    1. Goldschmidt, Hartmut
    2. Dimopoulos, Meletios A
    3. Rajkumar, S Vincent
    4. Weisel, Katja C
    5. Moreau, Philippe
    6. Chng, Wee-Joo
    7. Mikala, Gábor

    2020 - Forschungsinformationssystem des UKE
18. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

    1. Raab, Marc S
    2. Engelhardt, Monika
    3. Blank, Antje
    4. Goldschmidt, Hartmut
    5. Agis, Hermine
    6. Blau, Igor W
    7. Einsele, Hermann

    2020 - Forschungsinformationssystem des UKE
19. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    1. Facon, Thierry
    2. Kumar, Shaji
    3. Plesner, Torben
    4. Orlowski, Robert Z
    5. Moreau, Philippe
    6. Bahlis, Nizar
    7. Basu, Supratik

    2019 - Forschungsinformationssystem des UKE
20. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

    1. Garderet, Laurent
    2. Iacobelli, Simona
    3. Koster, Linda
    4. Goldschmidt, Hartmut
    5. Johansson, Jan-Erik
    6. Bourhis, Jean Henri
    7. Krejci, Marta

    2018 - Forschungsinformationssystem des UKE